ArticleAtherosclerosis plus2026
The association between albuminuria and coronary atherosclerotic burden in the general population.
Article in Atherosclerosis plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Albuminuria predicts cardiovascular events, but its association with prevalent subclinical coronary atherosclerosis is less well defined. We examined the cross-sectional relationship between urinary albumin-creatinine ratio (UACR) and coronary atherosclerotic burden in middle-aged adults from Sweden nationwide. Methods: UACR was measured in fasting spot urine in 9424 SCAPIS participants from Uppsala and Malmö. Coronary atherosclerosis was quantified by coronary artery calcium score (CACS; n = 9277) and coronary computed tomography angiography (CCTA; n = 9187) for stenosis. Linear regression related log(UACR) to log(CACS) with sequential adjustment: Model 1 (age, sex, ethnicity, site), Model 2 (+blood pressure, antihypertensive treatment, diabetes and antidiabetic treatment), and Model 3 (+LDL cholesterol, lipid-lowering treatment, smoking status, and eGFR). Logistic regression examined prevalent calcification (CACS>0) and stenosis; subgroup analyses excluded CKD, cardiovascular disease, hypertension, and diabetes stepwise. Results: Higher UACR was associated with higher CACS in the full cohort: β = 0.21 (95% CI 0.14-0.27), 0.08 (0.01-0.15), and 0.07 (0.00-0.14) in Models 1-3, respectively. Associations persisted after excluding CKD and cardiovascular disease (n = 8448): β = 0.20 (0.13-0.27), 0.19 (0.12-0.26), and 0.07 (0.00-0.15). With further exclusions, Model 3 estimates attenuated and were non-significant (no CKD/cardiovascular disease/hypertension: β = 0.06 [-0.02 to 0.14]; additionally no diabetes: β = 0.05 [-0.03 to 0.14]). In Model 1, each log-increase in UACR was associated with higher odds of CACS>0 (OR 1.08, 95% CI 1.05-1.12) and stenosis (OR 1.04, 95% CI 1.01-1.08), but associations attenuated and were non-significant in Models 2-3. Conclusions: Albuminuria is associated with greater coronary calcification burden, including in broadly healthy individuals, supporting the concept that albuminuria may reflect vascular disease early in the cardiovascular disease continuum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.